Related Experiment Video
Updated: Oct 9, 2026
Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
Published on: November 23, 2014
Responses to anti-angiogenic therapies
1Department of Pediatrics, Northwestern University Medical School, Chicago, Illinois, USA. apaller@nwu.edu
Abstract:
Vascular tumors occur in approximately 10% of infants, and range from small cherry-red lesions to large, life-threatening tumors. Although the majority of these tumors involute after several years, there are few therapeutic options and their use is limited by the risk of side-effects. The recent increase in understanding of angiogenesis has led to investigations of new antiangiogenic treatment options using models of vascular tumors in mice. These studies have demonstrated the success of a variety of antiangiogenic approaches, including systemic administration of the antiangiogenic proteins AGM-1470 and angiostatin or of the matrix metalloproteinase inhibitor batimastat, and gene gun therapy with interleukin-12. Although these trials provide further evidence of the role of angiogenesis in the enlargement of these vascular tumors, their potential utility and safety await future trials in patients.
Insights
Infant vascular tumors, common and sometimes severe, are being studied for new antiangiogenic therapies. Mouse models show promise for treatments targeting tumor blood vessel growth, but human trials are needed.
Area of Science:
- Oncology
- Vascular Biology
- Pediatric Medicine
Background:
- Vascular tumors affect about 10% of infants, varying in severity.
- Current treatments have limited options and potential side effects.
- Understanding angiogenesis is key to developing new therapies.
Purpose of the Study:
- To investigate novel antiangiogenic treatment strategies for infantile vascular tumors.
- To evaluate the efficacy of different antiangiogenic agents in preclinical models.
Main Methods:
- Utilized mouse models of vascular tumors.
- Administered antiangiogenic proteins (AGM-1470, angiostatin) and a matrix metalloproteinase inhibitor (batimastat).
- Investigated gene gun therapy with interleukin-12.
Main Results:
- Demonstrated success of various antiangiogenic approaches in mouse models.
- Provided evidence for the role of angiogenesis in tumor enlargement.
- Highlighted the potential of novel therapeutic strategies.
Conclusions:
- Preclinical studies show promise for antiangiogenic therapies in infantile vascular tumors.
- Further clinical trials are necessary to assess the utility and safety of these treatments in patients.
More Related Videos
Related Concept Videos
01:24Regulation of Angiogenesis and Blood Supply
01:27Tumor Immunotherapy
01:10Mechanism of Angiogenesis